Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Payables (2020 - 2026)

Maxcyte has reported Payables over the past 6 years, most recently at $1.4 million for Q4 2025.

  • Quarterly Payables rose 3.17% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, up 3.17% year-over-year, with the annual reading at $1.4 million for FY2025, 3.17% up from the prior year.
  • Payables was $1.4 million for Q4 2025 at Maxcyte, up from $1.3 million in the prior quarter.
  • Over five years, Payables peaked at $4.4 million in Q1 2022 and troughed at $292000.0 in Q4 2022.
  • The 5-year median for Payables is $1.4 million (2025), against an average of $1.6 million.
  • Year-over-year, Payables crashed 83.96% in 2022 and then soared 317.6% in 2024.
  • A 5-year view of Payables shows it stood at $1.8 million in 2021, then crashed by 83.96% to $292000.0 in 2022, then soared by 154.45% to $743000.0 in 2023, then soared by 82.77% to $1.4 million in 2024, then increased by 3.17% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Payables are $1.4 million (Q4 2025), $1.3 million (Q3 2025), and $1.2 million (Q2 2025).